A biotech company is working on therapies targeting age-related conditions like chronic inflammation, impaired healing, immune decline, and degenerative diseases, aiming to shift from treatment to prevention and improve overall healthspan.

The company's MSCs are designed to modulate aging mechanisms by reducing inflammation ('inflammaging'), decreasing cellular senescence, and supporting regenerative capacity through paracrine effects.

Their pipeline features a Phase III trial for knee osteoarthritis, using intra-articular MSC injections to reduce inflammation and cartilage degeneration, which could help maintain joint health in older adults.

Cynata is also exploring future endpoints related to healthspan, such as immune function, regenerative capacity, frailty, and mobility, with potential applications in neurodegeneration and systemic inflammation.

The company highlights that the scalability, standardization, and affordability of their platform could enable widespread use of MSC therapies for prevention and resilience against age-related decline.

Australian biotech Cynata Therapeutics is developing scalable, off-the-shelf mesenchymal stem cell (MSC) therapies using its proprietary Cymerus platform, which produces MSCs from induced pluripotent stem cells (iPSCs).

Cynata's research includes trials for kidney transplant patients to promote immune tolerance, reducing reliance on immunosuppressants, and for diabetic foot ulcers, showing an 80% wound closure rate, indicating potential for systemic vascular repair.